On their website
ILA: Our New Portfolio Addition they state
What is our Investment Plan?
We plan to hold a position in ILA for the next 3-5 years (and beyond) as it takes its dengue fever drug into phase 2/3 clinical trials.
We eventually may look to take some profits by selling up to ~20% of our holding (in line with ourholding policyand escrow conditions) if the share price materially rerates on the company successfully delivering on the key objectives listed above.
For New Portfolio Additions from November 19, 2024, changes to the minimum hold conditions are as follows:
(20min delay)